Abstract:Heparin and its low-molecular-weight heparin derivatives are widely used clinical anticoagulants. These drugs are critical for the practice of medicine in applications, including kidney dialysis, cardiopulmonary bypass, and in the management of venous thromboembolism. Currently, these drugs are derived from livestock, primarily porcine intestine and less frequently bovine intestine and bovine lung. The worldwide dependence on the pig as a single dominant animal species has made the supply chain for this critical drug quite fragile, leading to the search for other sources of these drugs, including the expanded use of bovine tissues. A number of laboratories are now also examining the similarities between heparin and low-molecular-weight heparins prepared from porcine and ovine tissues. This study was designed to compare low-molecular-weight heparin prepared from ovine heparin through chemical beta-elimination, a process currently used to prepare the low-molecular-weight heparin, enoxaparin. Using top-down, bottom-up, and compositional analyses as well as bioassays, low-molecular-weight heparin derived from ovine intestine was shown to closely resemble enoxaparin. Moreover, the compositions of daughter low-molecular-weight heparins prepared from three unfractionated ovine parent heparins were compared. Ovine enoxaparins had similar molecular weight and in vitro anticoagulant activities as Lovenox. Some disaccharide compositional, oligosaccharide composition at the reducing and nonreducing ends and intact chain compositional differences could be observed between porcine enoxaparin and ovine low-molecular-weight heparin. The similarity of these ovine and porcine heparin products suggests that their preclinical evaluation and ultimately clinical assessment is warranted.

A Unique Enoxaparin Derived from Bovine Intestinal Heparin: A Single Purification Step of the Starting Material Assures a Bovine Enoxaparin Like the Standard from Porcine Origin

Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin

Comparison Of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Enzymatic Generation of Highly Anticoagulant Bovine Intestinal Heparin.

From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods

General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market

Structural Characterization of Pharmaceutical Heparins Prepared from Different Animal Tissues.

Structure and Activity of a New Low-Molecular-weight Heparin Produced by Enzymatic Ultrafiltration.

Comprehensive Chromatographic Profiling and Structural Analysis of Key Anticoagulant Components in Enoxaparin

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

High Cell Density Cultivation of Recombinant Escherichia coli Strains Expressing 2- O -Sulfotransferase and C5-Epimerase for the Production of Bioengineered Heparin

Immobilized Enzymes to Convert N-sulfo, N-acetyl Heparosan to a Critical Intermediate in the Production of Bioengineered Heparin

Enzymatic access to the rare ΔUA (1→4) Glc 3, 6, N-sulfated heparin disaccharide, implications for heparin quality control

Development of effective heparin extraction method from pig by-products and analysis of their bioavailability

Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

SAX-HPLC and HSQC NMR Spectroscopy: Orthogonal Methods for Characterizing Heparin Batches Composition

A quantitative mass spectrometry method to differentiate bovine and ovine heparins from pharmaceutical porcine heparin

Preparation and Purification of Enoxaparin Sodium

Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies